Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Meet the Team
 

US

 
Denise Peterson

Denise Peterson

Denise.Peterson@informa.com

@PinkSheetDenise

Denise is Editor-In-Chief, Pharma US. Based in Informa’s Washington, DC office, she works with the US Scrip, Pink Sheet and In Vivo editorial team to provide the highest quality strategic insights for pharma's regulatory and commercial readers. Denise also collaborates closely with her European and APAC counterparts on editorial initiatives. She has had a colorful history reporting as a senior editor or managing editor on numerous issues for publications now part of Informa's Pink Sheet and Scrip resources. Those include Pink Sheet, Blue Sheet (NIH and public health programs), Beige Sheet (medical technology reimbursement) and Medicare Drug Focus. Her areas of expertise include legislation and health care reimbursement, and she’s also particularly interested in medical ethics. Outside of the office, her interests include culinary history and she is a long-time literacy volunteer.

Read more »


Matthew Hobbs

Nielsen Hobbs

Nielsen.Hobbs@informa.com

Nielsen has more than 20 years of experience covering the pharmaceutical industry, and writes frequently about the intersection of business, regulation, science and politics. Before joining Pink Sheet, he worked for Congressional Quarterly. Hobbs enjoys discussing BB-8 almost as much as he enjoys talking about 351(k). As Executive Editor, US Regulatory and Policy, Nielsen leads Pink Sheet’s US coverage and collaborates across Informa Pharma Intelligence’s publications. Pink Sheet offers readers insightful news and deep analysis on how to get your product developed, approved, and reimbursed. Pink Sheet’s team of reporters are experts on everything from ANDAs to Zika vaccines, offering lively stories that help subscribers understand the personalities, policies, and pain points that dictate whether their regulatory strategy succeeds or fails. Features such as the FDA Performance Tracker and Drug Review Profiles illuminate the inner workings of the agency. Hobbs is a frequent speaker and moderator at industry conferences.

Read more »


Mary Jo Laffler

Maryjo.Laffler@informa.com

@PinkSheetMaryJo

Mary Jo oversees commercial and R&D news for Informa’s pharmaceutical publications, working with a talented group of reporters and editors covering business and clinical topics. While she has a wide-ranging knowledge of the commercial and regulatory challenges facing the industry, her specialty is analyzing drug development news and R&D strategy. Mary Jo previously spent more than 15 years reporting on the pharmaceutical industry, including as executive editor and managing editor for Pink Sheet, executive editor for Pharmaceutical Approvals Monthly, and one of the first managing editors for Pink Sheet DAILY (the latter two publications now are part of Pink Sheet content). These roles involved following the drug development process from clinical trials to FDA review to approval and launch, as well as keeping track of broad industry trends and the commercial landscape. This broad experience helps to inform our current coverage. Mary Jo helped develop the FDA Performance Tracker and enjoys working with data to understand the trends affecting the industry.

Read more »

 

EUROPE

 
Eleanor Malone

Eleanor Malone

Eleanor.Malone@informa.com

@ScripEleanor

Eleanor directs editorial content produced by the Pharma Insights team (Scrip, Pink Sheet, In Vivo) in Europe, liaising closely with counterparts in the US and APAC. She oversees and contributes to daily analytical content based on biopharma industry developments and trends, interviewing key experts and industry leaders. Eleanor joined Informa in 2000 as companies reporter on Scrip, and has held a number of editorial roles on Informa's pharma and medtech publications. She has interviewed countless industry leaders and specialists, explored business developments and strategy, pipeline trends, policy and regulatory stories, delved into M&A, licensing, partnerships, financing, financial reports, clinical trial updates, market trends and more. Based in London, she regularly appears on conference panels and in the media to discuss matters relating to the biopharma industry. She has an MA in modern languages from the University of Edinburgh and previously worked as a translator of European business news for the Financial Times.

Read more »


 Maureen Kenny

Maureen Kenny

Maureen.Kenny@informa.com

@ScripRegMaureen

Maureen brings exclusive, business-critical content to the Pink Sheet audience, building upon her many years' experience as an editor and reporter on pharmaceutical industry matters. She manages a team of experts who specialize in European and rest-of-world regulatory affairs. Maureen has had a wide and varied career at Informa, with previous leadership roles including editor of Scrip Regulatory Affairs before its amalgamation into the Pink Sheet. Previous leadership roles also include being editor of Clinica Medtech Intelligence and acting editor of Scrip Intelligence. Maureen spent two years in New York covering the pharmaceutical industry for Scrip Intelligence in the US, Canada and, being a fluent Spanish speaker, Latin America. Past accomplishments include chairing the DIA EuroMeeting plenary session in Paris in April 2015. Maureen is based in London. Maureen specializes in European regulatory affairs, with a current focus on the European Medicines Agency and the broader EU pharmaceutical regulatory network. Brexit is already having a massive impact regulators on the industry and covering developments in these areas is a major current focus.

Read more »

 

ASIA

 
Ian Haydock

Ian Haydock

Ian.Haydock@informa.com

@ScripIanHaydock

Ian oversees content for the Asia-Pacific area, including in the commercial and policy/regulation areas, with a particular interest in company and pricing topics. He has been covering the region for more than 20 years as a writer and editor in the pharma sector.

Ian first moved to Japan in the 1990s and has covered a broad range of pharma industry topics, both across this market and the rest of Asia, including corporate, R&D, pricing and policy developments. After a stint as a Tokyo-based Japan and Asia editor for Scrip, he became managing editor of PharmAsia News (now part of Scrip/Pink Sheet) in 2014, and is a recipient of multiple Informa internal awards. He has a long personal and professional background in Asia, having grown up in Hong Kong, and follows regional regulatory harmonization and trade initiatives with interest. Ian lives in Tokyo with his wife and two sons.

Read more »

 

POLICY & REGULATORY

US

 

Michael Cipriano

Michael.Cipriano@informa.com

@mcipriano93

Michael is a writer based in Washington DC who covers FDA regulatory policy. He frequently attends and reports on FDA advisory committee meetings, public workshops and congressional hearings. He is a regular contributor to the Pink Sheet's FDA Performance Tracker, and additionally focuses on expanding coverage into the Latin and South America regions. Michael is a regular at FDA's White Oak campus covering advisory committee meetings and public workshops on a variety of drug development areas. He has also written on a wide range of congressional hearings on topics such as drug pricing, user fee reauthorizations, opioids and the 21st Century Cures Act. Michael is a weekly contributor to the Pink Sheet's "Keeping Track" column, and has authored several data-driven stories examining drug development trends. In his free time, Michael can be found cheering on - although often futilely - the New York Mets, Jets and Knicks.

Read more »


Bowman Cox

Bowman Cox

Bowman.Cox@informa.com

@GoldSheetBowman

Bowman Cox leads Informa's coverage of pharmaceutical manufacturing. He writes and edits articles on the challenges and opportunities that developments in science, technology and regulatory policy pose to manufacturers and their quality organizations. Bowman has followed various energy, environmental and health care sectors, writing news for pharmacists, chemists, engineers, lawyers and other professionals.He has moderated and presented at industry and journalism conferences, and has a background in product development, having helped launch publications, conferences and a journalism association. Bowman has a passion for connecting with professional communities, discovering their truths, telling their stories and helping them learn from each other. Other passions: crowd sourcing, data mining, classic movies and working on his basketball game.

Read more »


 Joanne Eglovitch

Joanne Eglovitch

Joanne.Eglovitch@informa.com

Joanne writes about manufacturing and quality issues for Pink Sheet. She covers international regulatory developments affecting the manufacturing of pharmaceuticals. Joanne has over 20 years of experience covering the regulated pharmaceutical and medical device industries. Before joining the Pink Sheet, she wrote about Medicare Part D and was editor of the "International Pharmaceutical Regulatory Monitor" and the "International Medical Device Regulatory Monitor." Past experience includes coverage of the mortgage finance industry and employment and training issues for various newsletters.

Read more »


Eileen Francis

Eileen Francis

Eileen.Francis@informa.com

Eileen is a reporter for HBW Insight, tracking developments in OTC drug research, manufacturing, regulation, finance, M&A and marketing. She favors stories on e-commerce trends and the industry's drive toward Rx-to-OTC drug switches. Eileen also contributes coverage on the dietary supplement industry. She has a keen eye for pieces that delve into the rising self-care movement and how it is raising the innovation bar for marketers.

Eileen started her journalism career as a reporter for Rose Sheet covering news relating to personal care R&D, new products, M&A and marketing, before assuming the role of managing editor. She later joined the Tan Sheet, broadening her expertise to OTC drugs and dietary supplements. Both Rose Sheet and Tan Sheet now are part of HBW Insight. Early in her career, she served as a writer for a lobbying firm and as a blogger covering patent law news for an international law firm. Outside of Informa, her freelance work includes articles on business, art and travel. When not sitting behind her desk, Eileen is usually found running on a trail or treadmill.

Read more »


Derrick Gingery

Derrick Gingery

Derrick.Gingery@informa.com

@dgingery

Derrick covers US FDA regulatory and policy issues, helping drug and biologic sponsors and other stakeholders understand the drug development, review and approval landscape. Derrick focuses on the US FDA user fee programs, regulations and policy for new and generic drugs, biologics and biosimilars, advisory committee and other agency activities, as well as federal legislation and budget matters on Capitol Hill. An award-winning journalist, he was a reporter for several community newspapers and a business journal prior to joining Informa. When not following FDA, Derrick is keeping tabs on Indiana University basketball.

Read more »


Cathy Kelly

Cathy Kelly

Catherine.Kelly@informa.com

A part of the regulatory and policy team for Informa's Pharma Intelligence group, Cathy is widely recognized for expertise on prescription drug reimbursement/market access and pricing issues. She regularly contributes to Pink Sheet and Scrip. Her focus is on developments in the US commercial and government insurance sectors as they shift toward a system of payment based on value.

Cathy has covered prescription drug reimbursement issues for more than 12 years, starting with the implementation of the Medicare Part D program. She has written extensively about developments in all the major US insurance sectors -- Medicare (Parts D and B), Medicaid and the employer-sponsored market. She has closely followed the increasing influence of pharmacy benefit managers and their use of formulary negotiations and rebates to control pricing. Cathy also has covered the implementation of frameworks for assessing drug value by medical professional organizations and the Institute for Clinical and Economic Review and is watching with interest as the government develops new policies aimed at lowering drug pricing. She has worked as a health care reporter and editor for more than three decades while raising three daughters. Cathy lives in Bethesda, MD with her husband Sean.

Read more »


Brenda Sandburg

Brenda Sandburg

Brenda.Sandburg@informa.com

@brendasandburg

Brenda writes breaking news stories and feature articles about all areas of the biopharmaceutical industry with a focus on litigation, patents and intellectual property issues, and regulatory policies of the Food and Drug Administration, including biosimilars development. Brenda worked at the Pink Sheet and a sibling publication from 1981 to 1993, returning in 2007. In between she was a reporter for America Lawyer Magazine and a daily legal newspaper in San Francisco where she won several awards, including first place in investigative reporting for the first story ever written about patent trolls. This experience has given her an expertise in legal and regulatory issues. She covers all aspects of FDA, including advisory committee meetings and drug approvals, and legal issues, including patent suits, Supreme Court cases, and government investigations. An amateur photographer, Brenda enjoys including photos with articles.

Read more »


Bridget Silverman

Bridget Silverman

Bridget.Silverman@informa.com

Bridget Silverman has been covering FDA for the Pink Sheet since David Kessler was commissioner, with a focus on the US drug review and approval process. She oversees the FDA Performance Tracker suite of interactive charts and the
Drug Review Profile series of deep dives into FDA review decisions. Bridget is especially interested in how regulatory reforms and policy initiatives affect clinical trial design and R&D strategy. She covered the commercial and financial beats for the Pink Sheet before focusing on drug development as an editor on Pharmaceutical Approvals Monthly and the NDA Pipeline, where she helped to develop database products that inform our current regulatory tracking features. In her down time, Bridget reads mystery novels and keeps track of her family and three dogs.

Read more »


Malcolm Spicer

Malcolm Spicer

Malcolm.Spicer@informa.com

Malcolm has expertly covered the OTC drug and nutritional supplement industries and markets for more than a decade and currently is Senior Editor at Informa Pharma Intelligence’s HBW Insights. He provides authoritative and highly analytical insight into how and why the US Food and Drug Administration regulates OTC drug, including homeopathics, and nutritional supplement manufacturing and marketing and also how companies competing in these industries can most efficiently and effectively comply with FDA regulations, the cornerstone for their success. Previously, Malcolm covered these industries for the Tan Sheet (now part of HBW Insight), joining the Tan Sheet as Managing Editor in August 2006. He has continued to lead coverage of consumer health products as the consumer sector content has evolved at Informa and he collaborates on coverage strategy with editors at Pink Sheet and other publications. Malcolm also has had experience in covering US health care policy and the global telecommunications industry as well as reporting on topics from litigation to lifestyles, and from crime to commerce for daily newspapers.

Read more »


Sue Sutter

Sue Sutter

Sue.Sutter@informa.com

@PinkSheetSutter

Sue is a senior editor based in Washington, DC, and primarily covers US drug, biologic and biosimilar regulation and policy across therapeutic areas, with an emphasis on advisory committee reviews and FDA approvals. She also covers generic drug and biosimilar patent litigation and other legal issues. Sue has reported on the prescription and over-the-counter drug industries since 1999 for various publications now under the umbrella of Informa Business Intelligence, including Pink Sheet, "The Pink Sheet" DAILY, "The Tan Sheet" and Scrip. Previously she worked as an editor for Mealey's Litigation Reports (now part of Lexis-Nexis), writing about asbestos, toxic tort and fen-phen litigation. She grew up in South Jersey, where her love for the Philadelphia Phillies and Eagles and home-grown tomatoes was deeply engrained.

Read more »

 

EUROPE

 
Neena Brizmohun

Neena Brizmohun

Neena.Brizmohun@informa.com

@ScripRegNeena

Neena has over 20 years of experience covering regulatory, business and market access developments impacting pharmaceutical and medical device companies.

She explores the challenges and opportunities that developments worldwide introduce for industry and regulators. Her areas of expertise include regulatory schemes for getting products to market faster. Neena's other specialist areas include new medicines coming to market in the EU, clinical trials, post-marketing safety monitoring, transparency policies relating to the publication of trial data, and global harmonization initiatives for pharma and medtech.

A scientist by training, Neena started her journalistic career at Informa in 1997. Before becoming a journalist she worked as a biomedical scientist at St Thomas' Hospital in London for 10 years.

Read more »


Ian Schofield

Ian.Schofield@informa.com

@ScripIanS

Ian writes for the Pink Sheet, Scrip and In Vivo on a range of issues affecting the life sciences sector, with a focus on regulatory, political, legal and scientific affairs in the EU, Australia, Canada and elsewhere. His articles and analysis provide readers with valuable insights into the significance of regulatory and legislative developments in those markets. Ian’s specialist areas include biosimilars, generic and orphan drugs, market access, and intellectual property issues. A modern languages graduate, he worked in the European travel industry before joining Scrip in 1985 as a reporter covering the French and Italian markets. He subsequently held posts including Deputy Editor of Scrip and later Principal Analyst at Informa, before taking up his current position. As well as writing news, features and analysis, Ian is part of the Ask the Analyst team that produces on-demand tailored reports for subscribers. His non-work interests include cycling, travel, and playing traditional Scottish music.

Read more »


Vibha Sharma

Vibha Sharma

Vibha.Sharma@informa.com

@ScripRegVibha

Vibha Sharma is a senior reporter covering pharmaceutical and medtech regulatory developments across the globe. She plays a key role in tracking and writing about news of important regulatory issues affecting the sectors, and explaining their implications for industry. Vibha's fields of interest include the EU Pharmacovigilance legislation and the EU Pediatrics Regulation on which she has written several exclusive articles from various industry conferences. She has also commissioned some pieces of expert analysis on major developments in the pharma and medtech regulatory arenas.
Before joining Informa, she was principal correspondent with India's national newspaper Hindustan Times, where she reported on health and medical issues, besides several other topics. She has also worked with two other Indian national dailies, The Indian Express and The Asian Age.

Read more »

 

COMMERCIAL

US

 

Joseph Haas

Joseph.Haas@informa.com

Joe has covered a wide range of biopharmaceutical stories for the past 11 years and contributes to Pink Sheet, Scrip and related Informa publications. His specialties include business development, commercial strategies and infectious diseases. Joe began reporting on the pharmaceutical industry upon joining the Pink Sheet in 2007. Key developments he has analyzed include Genzyme’s acquisition by Sanofi; the dynamics of the hepatitis C market from the development of telaprevir and boceprevir through the market’s emergence into a mature therapeutic space; nascent R&D efforts in NASH; and deal-making among pharma, biotechs and academic/research institutions.

Read more »


Mandy Jackson

Mandy.Jackson@informa.com

@ScripMandy

Mandy is Managing Editor, US Commercial News. Mandy reports on daily biopharma developments, writes feature stories, produces the Finance Watch column and oversees Emerging Company Profiles. She covers finance, start-ups, dealmaking, clinical trial results, commercial competition and corporate strategy.

Mandy regularly interviews everyone from big pharma CEOs to biotech start-up founders, enhancing her expertise on industry trends and market dynamics. She also is interested in drug pricing and novel reimbursement strategies, new treatments in areas of true unmet need, diversity in the biopharma industry and novel approaches to drug development. She has been a business reporter since 2000, covering biopharma, biotech law and commercial real estate.

Read more »


Jessica Merrill

Jessica.Merrill@informa.com

@Jessicaemerrill

Jessica is a senior editor at Informa, contributing most frequently to daily pharmaceutical coverage in Scrip and Pink Sheet. With a lengthy career covering the pharmaceutical sector, she specializes primarily in business and commercial news, launch strategy, M&A and market access issues. She is based in New York City. Jessica has been covering the pharmaceutical sector for more than 12 years after initially covering the cosmetics industry for Rose Sheet and following a career in newspaper journalism. She covers a wide range of business and commercial news, but specializes in launch strategy, M&A and market access issues. Jessica enjoys reading, hiking and spending time with her family.

Read more »


Leah Samuel

Leah.Samuel@informa.com

Based in Boston, Leah was most recently with the Boston Globe’s STAT news publication – where she reported on biomedical research as well as general interest issues, like the growing phenomenon of people taking Uber to the ER and diversity in medical schools. She has decades of experience with investigative reporting and award-winning features writing, and has embraced the chance to take a deeper dive into the biopharma industry.

Read more »

 

EUROPE

 
Francesca Bruce

Francesca Bruce

Francesca.Bruce@informa.com

@ScripFrancesca

Francesca has been writing news and analysis relating to the pharmaceutical industry since 2008, paying special attention to market access developments across the world. Francesca regularly speaks to a range of stakeholders from across the sector to bring readers insights on key developments. Francesca writes about a broad range of policy and regulatory topics, including intellectual property rights. However, her main areas of expertise are pricing and reimbursement and how medicines may or may not make it to patients. She writes about developments in Europe but is also expanding coverage in emerging markets, including Latin America and the Middle East. Francesca writes for Scrip, Pink Sheet and In Vivo.

Read more »


John Davis

John Davis

John.Davis@informa.com

@ScripJohnD

John writes news and analysis about European biotech and pharma companies, including their product development, marketing, financial prospects and personnel. A biochemical pharmacologist by training, John observes and describes the way European biotech and pharmaceutical companies are in the business of trying to triumph over poor health and disease. He has an intense interest in how medicines work, what drives their development, and the business strategies of the companies involved, including their inter-company collaborations, their ability to raise financing, revenues and income, and moves to provide a return to investors, within the context of marketing medicines. He interviews company executives and entrepreneurs for insights and background to produce forward-looking news and analysis, in-depth reports, and market commentary. In his spare time, John is a DIY enthusiast and a member of the RSPB and the National Trust.

Read more »


Kevin Grogan

Kevin.Grogan@informa.com

@kevinatgrogan

Kevin has been writing about pharmaceuticals for over twenty years in roles that have included online editor for PharmaTimes. After four years freelancing, which involved writing for all the principal titles in the sector, as well as consultancy work with major pharma companies, he joined Scrip in 2017. Covering all aspects of the pharma industry and across all therapeutic areas, Kevin has interviewed pretty much all the leading figures in the sector. A regular attendee at financial and medical conferences (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss the industry. Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at Catholic newspaper The Universe and contributed articles to the likes of The Independent and the Manchester Evening News on football.

Read more »


Alex Shimmings

Alexandra Shimmings

Alex.Shimmings@informa.com

@ScripAlexS

Alex has been covering the international pharmaceutical and biotech sectors for more than 20 years. She is currently the Executive Editor - Commercial/R&D for Scrip, Pink Sheet and In Vivo and her main work interests lie in novel drugs, and developments in pharma and biotech R&D. Alex has held a variety of editorial positions of increasing seniority on Scrip since joining the publication as a science reporter in 1998. Currently, she heads up the European editorial team coverage of commercial and R&D developments for Scrip, Pink Sheet and In Vivo, while also writing news, analysis and features for the publications. Over the years, Alex has covered breakthroughs in R&D in a range of therapeutic areas, including infectious diseases, cardiology and cancer, and she enjoys interviewing key industry players and opinion leaders. Alex also has a keen interest in medical history, and a degree in Biochemistry and Microbiology.

Read more »


Sten Stovall

Sten.Stovall@informa.com

@StenStovall

Sten writes daily news analyses and feature stories for Informa publications, focusing on a wide range of therapeutic areas, product R&D developments, likely regulatory pathways and corporate business strategies. A journalist for more than 40 years, Sten is a trained as a political economist whose previous employers include Reuters and Bloomberg. He has been covering the life sciences sector since 2004. Before joining the Informa content team in 2012, Sten was European healthcare editor and writer at Dow Jones Newswires and the Wall Street Journal, based in London. He has a BA in Economics and Politics from Boston College, Mass., and a Postgraduate Certificate in Digital Media Management from Birkbeck College, London.

Read more »

 

ASIA

 
Anju Ghanguarde

Anju Ghangurde

Anju.Ghangurde@informa.com

@ScripAnjuG

Anju is Deputy Asia Editor at Informa’s Scrip & Pink Sheet. She has over two decades of experience in journalism including stints at India's leading financial dailies. Based in Mumbai, India, she covers a range of topics across the pharma and biosimilar landscape. Drug pricing, policy and regulatory affairs, M&A and patents are areas of special interest to her. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office. Anju has extensive experience at India's mainstream financial dailies, The Economic Times, The Hindu Business Line and The Financial Express. As Corporate Bureau Chief (Mumbai), she led a team of reporters at The Financial Express prior to joining Scrip. She’s been associated with Scrip since 2001, when it was part of PJB Publications.
Anju enjoys covering pharma conferences and interviewing industry heads and regulatory/government officials in the region. Occasionally, she also moderates industry panels at key events.
She follows racket sports closely and has previously received recognition at the national level in India. She loves the hills and when not reporting on pharma believes that nature is the best therapy.

Read more »


 Jung Won Shin

Jung Won Shin

JungWon.Shin@informa.com

Jung Won covers pharma/biotech industry and regulatory news in South Korea, including major breaking news, interviews with key officials, policy and regulatory developments as well as other feature stories that provide insight into the Korean pharma/biotech market. Jung Won has worked previously for Dow Jones Newswires, covering various industry sectors and the economy, providing her with an ability to work to tight deadlines. She has played a key role in expanding Scrip and Pink Sheet's coverage of the important South Korean market, including biosimilar companies, emerging bioventures, and important policy, pricing and regulatory developments.

Read more »


Brian Yang

Brian Yang

Brian.Yang@informa.com

@bhxyang

Experienced China hand on healthcare and biopharma hot-button issues, drug reforms, pricing and market access, the biotech boom
and IPOs. Brian's on-the-ground, deep-dive and trend-spotting analysis has won wide praise from those interested in this key market.. Beijing-based senior editor in charge of overall China coverage
within the APAC Pharma news team. A veteran journalist, he has
written extensively on pharmaceutical R&D, regulatory affairs and market access. Brian has led a team of writers to provide industry-leading coverage on many key issues in the second-largest heatlhcare market.
He has worked as a foreign affairs correspondent and web editor for both TV and radio networks, and is trilingual in Chinese, English and Japanese. Outside work, Brian has run in dozens of marathons and one triathlon.

Read more »


Vibha Ravi

Vibha Ravi

vibha.ravi@informa.com

Vibha Ravi has joined the APAC content team as a subeditor and writer for Scrip and Pink Sheet, based in Mumbai. She has a degree in business administration and extensive senior level writing, editing and content management experience, covering the pharma industry for mainstream Indian financial daily Business Standard and then for agency AFX-Asia.

Vibha has worn a corporate hat in a stint at Thomas Cook (India), giving her a deeper insight into the functioning and drivers of a business. She is interested in news and analysis of biopharma companies, including corporate strategies, marketing, product development and financial performance.

Most recently, Vibha worked as an independent contributor to various publications apart from running her own website. With a degree in botany, she is an observer of nature and a keen photographer outside of office.

Read more »

 

LEADERSHIP

 

Mike Ward

Mike.Ward@informa.com

@ScripMikeWard

Mike has been writing, analyzing and commenting on the life sciences industry for more than 30 years as a journalist and investment bank analyst. Mike has focused on business models, R&D strategies and how to finance innovation, and is often called upon by the industry's key stakeholders to provide thought leadership. In 2010 he was named European Mediscience Commentator of the Year and has appeared on the shortlist for that award on numerous occasions.

When not commentating on all things pharma, Mike is engaged actively in pub quizzes, either as a competitor or a compiler. He is also a qualified FA soccer coach.

Read more »


Phil Jarvis

Phil.Jarvis@informa.com

Phil graduated from The University of Bath in 1997 and embarked on a brief career as a crop protection research scientist. In January 2000 Phil made a sideways jump into publishing, joining PJB Publications as a report writer with the crop protection business.

Since then Phil has built his knowledge of the publishing business in a variety of content and commercial roles. In 2008 Phil moved to Informa's Pharma business as publisher of Scrip.

Phil now leads this business as 'Head of Insight' for the Pharma intelligence vertical within Informa's Business Intelligence division. He works with colleagues across the vertical to deliver an integrated, market-leading Pharma intelligence service encompassing insights, intelligence and consulting.

     
UsernamePublicRestriction

Register